1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Panic Disorders - Pipeline Review, H1 2013

Panic Disorders - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Panic Disorders - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Panic Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Panic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Panic Disorders. Panic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Panic Disorders.
- A review of the Panic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Panic Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Panic Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Panic Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Panic Disorders - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Panic Disorders Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Panic Disorders 6
Panic Disorders Therapeutics under Development by Companies 8
Early Clinical Stage Products 9
Comparative Analysis 9
Pre-Clinical Stage Products 10
Comparative Analysis 10
Panic Disorders Therapeutics - Products under Development by Companies 11
Companies Involved in Panic Disorders Therapeutics Development 12
Conformetrix Ltd 12
Panic Disorders - Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Molecule Type 14
Drug Profiles 16
NSD-721 - Drug Profile 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Drug Targetting Orexin-1 Receptor - Drug Profile 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
cycloserine - Drug Profile 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Panic Disorders Therapeutics - Discontinued Products 19
Panic Disorders Therapeutics - Dormant Products 20
Panic Disorders - Product Development Milestones 21
Featured News and Press Releases 21
Mar 30, 2011: Bionomics Successfully Completes Two Phase Ib Clinical Trials Of BNC210 21
Oct 01, 2004: IVAX Receives Final Approval on Fluoxetine Tablets and Capsules. 22
Jan 29, 2002: Teva Announces Final Approval for Fluoxetine 10, 20 and 40 mg Capsules 22
Aug 02, 2001: Teva Announces Final Approval of Fluoxetine Oral Solution 22
Jun 03, 2001: Teva Announces Tentative Approval for Fluoxetine 10mg 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables


Number of Products Under Development for Panic Disorders, H1 2013 6
Products under Development for Panic Disorders - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Early Clinical Stage Development, H1 2013 9
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Conformetrix Ltd, H1 2013 12
Assessment by Monotherapy Products, H1 2013 13
Assessment by Stage and Molecule Type, H1 2013 15
Panic Disorders Therapeutics - Discontinued Products 19
Panic Disorders Therapeutics - Dormant Products 20

List of Figures


Number of Products under Development for Panic Disorders, H1 2013 6
Products under Development for Panic Disorders - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Early Clinical Stage Products, H1 2013 9
Pre-Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 13
Assessment by Molecule Type, H1 2013 14
Assessment by Stage and Molecule Type, H1 2013 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Anxiety Disorders - Pipeline Review, H2 2016

Anxiety Disorders - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Anxiety Disorders - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Anxiety Disorders - Pipeline Review, H2 2016’, provides an overview of the Anxiety Disorders pipeline landscape. The ...

Brainsway Ltd. (BRIN) - Product Pipeline Analysis, 2016 Update

Brainsway Ltd. (BRIN) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • August 2016
  • by Global Data

Summary Brainsway Ltd. (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychopathological ...

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • July 2016
  • by Global Markets Direct

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016’, provides an overview of the Post-Traumatic ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.